MarketCap
Facebook
X
Telegram
Opiant Pharmaceuticals Balance Sheet 2021-2005 | OPNT
Brief overview of Opiant Pharmaceuticals's assets and capital
The balance sheet is assessed across five available annual reports spanning 2017 to 2021.
Assets rose from $20.8 million to $70.4 million, a gain of +239%, while CAGR was about 35.7%. The balance sheet expanded rapidly.
Liabilities grew more slowly than assets: +203.5% versus +239%. Expansion relied more on equity, improving funding quality.
Equity funds 66.5% of assets versus 62.6% initially. This creates a conservative balance sheet structure.
The period ended with net cash: net debt stood at -$36.8 million. This supports financial flexibility.
Cash represents 53.7% of assets versus 39.1% initially, showing how the immediate liquidity reserve changed.
The accumulated result is -$61.7 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
Opiant Pharmaceuticals's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet Opiant Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-36.8 M | -29.3 M | -30.2 M | -24.6 M | -6.87 M | -1.32 M | -434 K | -255 K | -574 K | 2.72 M | -51.8 K | - | - | - | - | - | - |
Long Term Debt |
673 K | 18.7 M | 255 K | - | - | - | - | - | - | 2.74 M | - | - | - | - | - | - | - |
Long Term Debt Current |
338 K | 282 K | 517 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 18.7 M | 255 K | 2.7 M | 2.31 M | 2.35 M | 5.3 M | 1.41 M | 750 K | 10.5 M | 308 K | - | - | - | - | - | - |
Total Current Liabilities |
6.85 M | 6.42 M | 5.61 M | 9.83 M | 5.66 M | 4.24 M | 3.57 M | 1.97 M | 883 K | 664 K | - | - | - | - | - | - | - |
Total Liabilities |
23.6 M | 25.1 M | 5.86 M | 12.5 M | 7.77 M | 6.59 M | 8.87 M | 3.38 M | 1.63 M | 664 K | 416 K | - | - | - | - | - | - |
Deferred Revenue |
16.6 K | 355 K | 918 K | 1.21 M | 379 K | 250 K | - | - | - | 47.9 M | - | - | - | - | - | - | - |
Retained Earnings |
-61.7 M | -64.7 M | -62.8 M | -74.4 M | -53.2 M | -61.2 M | -53.4 M | -46.3 M | -34.9 M | 13.7 M | -11.5 M | - | - | - | - | - | - |
Total Assets |
70.4 M | 60.6 M | 40.3 M | 29.4 M | 20.8 M | 1.88 M | 488 K | 301 K | 643 K | 45 K | 77.7 K | - | - | - | - | - | - |
Cash and Cash Equivalents |
37.9 M | 48.3 M | 31 M | 24.6 M | 8.12 M | 1.48 M | 434 K | 255 K | 599 K | 20.4 K | 51.8 K | 2.3 K | - | - | - | - | - |
Book Value |
46.8 M | 35.5 M | 34.4 M | 16.9 M | 13 M | -4.7 M | -8.39 M | -3.08 M | -990 K | -619 K | -339 K | - | - | - | - | - | - |
Total Shareholders Equity |
46.8 M | 35.5 M | 34.4 M | 16.9 M | 13 M | -4.7 M | -8.39 M | -3.08 M | -990 K | -619 K | -339 K | -637 K | 290 | -28.2 K | -10.2 K | 23.4 K | - |
All numbers in USD currency
Quarterly Balance Sheet Opiant Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 12.3 M | 13.7 M | 13.7 M | 16.1 M | 18.9 M | 18.8 M | 18.8 M | 18.7 M | - | 34.8 K | 131 K | 255 K | 358 K | 255 K | 255 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 14.3 M | 16.7 M | 19.6 M | 19.6 M | 18.8 M | 18.7 M | - | 34.8 K | 131 K | 255 K | 358 K | 255 K | 255 K | 2.7 M | 402 K | 2.08 M | 2.16 M | 2.12 M | 2.4 M | 2.12 M | 2.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | 21.4 M | 19.2 M | 21.1 M | 23.6 M | 27 M | 25.4 M | 24.9 M | 25.1 M | 6.7 M | 5.14 M | 4.46 M | 5.86 M | 9.76 M | 8.76 M | 9.47 M | 12.5 M | 4.13 M | 6.42 M | 7.82 M | 7.77 M | 5.52 M | 7.05 M | 7.1 M | 6.23 M | 6.17 M | 6.23 M | 9.71 M | 7.11 M | 8.26 M | 7.11 M | 5.34 M | 2.15 M | 2.5 M | 2.15 M | 2.2 M | 1.2 M | 1.19 M | 1.2 M | 865 K | 368 K | 534 K | 368 K | 270 K | - | 270 K | 416 K | 416 K |
Deferred Revenue |
- | - | - | - | 16.6 K | - | - | 859 K | 355 K | 360 K | 817 K | 842 K | 918 K | 1.36 M | 1.37 M | 757 K | 1.21 M | 660 K | 760 K | 277 K | 379 K | 195 K | 750 K | 250 K | - | 250 K | 250 K | 250 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | -95.5 M | -85.6 M | -73.9 M | -61.7 M | -62.4 M | -65.8 M | -67.5 M | -64.7 M | -64 M | -64.7 M | -64.5 M | -62.8 M | -63.9 M | -74.6 M | -76.2 M | -74.4 M | -64.9 M | -64 M | -62.6 M | -53.2 M | -54.3 M | -51.1 M | -61.8 M | -60.5 M | -60.1 M | -60.5 M | -64.5 M | -49.9 M | -51.7 M | -49.9 M | -47.1 M | - | -47.1 M | -46.3 M | -46.3 M | - | - | -34.9 M | - | - | - | - | - | - | - | - | - |
Total Assets |
- | 42 M | 48.8 M | 60.3 M | 70.4 M | 69 M | 61.8 M | 58.9 M | 60.6 M | 42.2 M | 39.4 M | 38.3 M | 40.3 M | 41.4 M | 28.8 M | 26.3 M | 29.4 M | 29.3 M | 14.8 M | 13.8 M | 20.8 M | 9.8 M | 13 M | 1.98 M | 1.33 M | 2.46 M | 1.33 M | 493 K | 1.11 M | 1.41 M | 1.11 M | 1.7 M | 447 K | 245 K | 447 K | 359 K | 176 K | 663 K | 176 K | 26.4 K | 72.8 K | 50.2 K | 72.8 K | 38.3 K | - | 38.3 K | 77.7 K | 77.7 K |
Cash and Cash Equivalents |
- | 35.4 M | 40.2 M | 48.3 M | 37.9 M | 35.3 M | 33.4 M | 35.4 M | 48.3 M | 31.1 M | 30.5 M | 32.2 M | 31 M | 23.2 M | 23.9 M | 23.8 M | 24.6 M | 24.8 M | 11.2 M | 11.3 M | 8.12 M | 9.68 M | 12.9 M | 1.18 M | 13.2 M | 2.36 M | 1.28 M | 455 K | 1.06 M | 1.34 M | 1.06 M | 1.15 M | 420 K | 181 K | 420 K | 324 K | 152 K | 610 K | 152 K | 2.18 K | 47.4 K | 25 K | 47.4 K | 12.6 K | 1.12 K | 12.6 K | 51.8 K | 12.6 K |
Book Value |
- | 20.5 M | 29.6 M | 39.3 M | 46.8 M | 42 M | 36.4 M | 34 M | 35.5 M | 35.5 M | 34.3 M | 33.8 M | 34.4 M | 31.6 M | 20.1 M | 16.8 M | 16.9 M | 25.2 M | 8.38 M | 5.93 M | 13 M | 4.29 M | 5.95 M | -5.12 M | -4.9 M | -3.71 M | -4.9 M | -9.22 M | -6 M | -6.85 M | -6 M | -3.63 M | -1.7 M | -2.26 M | -1.7 M | -1.84 M | -1.03 M | -526 K | -1.03 M | -839 K | -295 K | -484 K | -295 K | -231 K | - | -231 K | -339 K | -339 K |
Total Shareholders Equity |
- | 20.5 M | 29.6 M | 39.3 M | 46.8 M | 42 M | 36.4 M | 34 M | 35.5 M | 35.5 M | 34.3 M | 33.8 M | 34.4 M | 31.6 M | 20.1 M | 16.8 M | 16.9 M | 25.2 M | 8.38 M | 5.93 M | 13 M | 4.29 M | 5.95 M | -5.12 M | -4.9 M | -3.71 M | -4.9 M | -9.22 M | -6 M | -6.85 M | -6 M | -3.63 M | -1.7 M | -2.26 M | -1.7 M | -1.84 M | -1.03 M | -526 K | -1.03 M | -839 K | -295 K | -484 K | -295 K | -231 K | - | -231 K | -339 K | -339 K |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Opiant Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
Israel
Britain
Singapore
USA
China
Japan
Canada